# Chronic pulmonary thrombepigen(CPT)

miRNAs for the diagnostic of chronic thromboembolic pulmonary hypertension.

## CLINICAL NEED / NEED


thromboembolic Chronic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism а (PE), characterized by thromboembolic material inside pulmonary arteries that causes an increase in the pulmonary vascular resistance, heart failure and even death. Currently, there is not **biomarkers** for effective early an diagnostic and the correct identification can take among 14 and 24 months, with a late starting of the treatment.

# 

Our group has identified a **new panel of miARNs** that allows a **non-invasive diagnostic** of CTPEH, and also distinguish between patients with PE or CTPEH or even the prognosis of PE.

#### COMPETITIVE ADVANTAGE

Nowadays, there is **no precise and specific diagnosis** for CTEPH **nor distinction among PE and CTEPH.** Moreover, the diagnostic test presented allows a **prognosis of PE**.




### INTELLECTUAL PROPERTY

**European patent** (P202231096) application was submitted 22 of December 2022. FRCB-IDIBAPS, HCB, SAS and IIS La Fe share joint ownership.

#### DEVELOPMENT

The **Proof of Concept** has been achieved and the team is working to achieve **TRL4**: validation





Partners for **license agreement** or a **co-development**.



Dr Joan Albert Barbera Dra Olga Tura Dra Remedios Otero Dra Veronica Sanchez Lopez Dra Pilar Medina Dra Julia Oto

CONTACT DETAILS

Knowledge and Technology Transfer Office innova@recerca.clinic.cat

September 2023